Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the Unit…
FAIL · Does not pass the screen
18.64 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 18.64 against the desk's fair-value range, base estimate 35.80, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price18.64 USD
Fair value35.80
Ethical score70.0/100
Our investment reviews on this name
2026-09-04Read Markup21.30-12.5% to today
2026-08-04Read Distribution18.55+0.5% to today
2026-07-02Read Markup35.87-48.0% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Legend Biotech Corporation holds its Markdown at $18.64. Consolidating, no directional conviction, held for 27 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 27 days
Price at the screen
$18.64
Valuation
N/A trailing · 17.75 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.40
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.86%
Below 33%
Interest-bearing debt is just 23.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.29%
Below 33%
Cash held in interest-bearing accounts and securities is 0.3% of assets, under the one-third limit.
Pass
Receivables
52.78%
Below 49%
Money owed to the company is 52.8% of assets, above the 49% limit.
Fail
Revenue purity
3.90%
Below 5%
Only 3.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 92.1% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +160% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cell Therapy Growth Story Still Burning Cash
Picture a hospital ward where one new cell therapy can rewrite outcomes for blood cancer patients. Legend Biotech is scaling that kind of treatment, with revenue already jumping 56 percent a year. The shares sit at a steep discount to our fair value, yet the business remains loss-making and carries an unknown competitive edge.
Forward earnings sit on a reasonable 20.3 times multiple, but profit margins of minus 22 percent and a negative 25 percent return on equity show the company is still investing heavily just to reach commercial scale. Analyst targets cluster higher, yet those forecasts rest on successful launches and steady reimbursement, none of which is guaranteed.
Risk sits high because the firm has yet to prove durable profits or a defendable position against larger rivals. Currency moves, trial setbacks and funding needs could all widen the gap between promise and delivery. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LEGN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Markup · changed$21.30+14.8%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (15 analysts) rates it buy, with a mean price target of $55.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 48.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (15 analysts) rates it buy, with a mean price target of $55.
2026-07-18Markup$35.87+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (15 analysts) rates it buy, with a mean price target of $55.
2026-07-03Markup$35.87+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$35.87Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
